Haploidentical vs Matched Unrelated Donor Age Impacts Survival in Patients With ALL
Researchers sought to determine the impact of donor age on survival in patients with ALL who undergo HCT with PTCy for GVHD prophylaxis.
Researchers sought to determine the impact of donor age on survival in patients with ALL who undergo HCT with PTCy for GVHD prophylaxis.
The letter states that the application cannot be approved in its present form.
Researchers sought to determine whether greater Vδ2-positive T-cell recovery would impact mortality for patients with AML who undergo haplo-HCT.
59 percent of individuals had organ impairment at one year; breathlessness, cognitive dysfunction, poor HRQoL also common.
Researchers sought to determine whether a larger dose of decitabine prior to allo-HSCT would improve outcomes in patients with AML.
Researchers sought to determine whether Orca-T could improve relapse and survival outcomes compared with historical controls for patients receiving allo-HSCT.
Researchers sought to determine whether adding RGI-2001 to a calcineurin inhibitor and methotrexate or mycophenolate mofetil would help prevent acute GVHD.
Researchers assessed whether PTCy with sirolimus would reduce median time to immunosuppression withdrawal and a lower rate of chronic GVHD following allo-HCT.
Researchers sought to determine whether itacitinib would be an effective treatment for acute GVHD through a multicenter, phase 2 trial.
Researchers sought to determine whether ibrutinib could improve outcomes in the frontline setting of cGVHD.